tbuckley/cabot-search huggingface dataset:
Management of the Severely Anemic Jehovah's Witness
Authors: David Green
Journal: Annals of Internal Medicine (1993)

Letters15 July 1993Management of the Severely Anemic Jehovah's WitnessDavid Green, MDDavid Green, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-119-2-199307150-00019 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Albumin is added as a stabilizer to recombinant human erythropoietin and the newly licensed recombinant human antihemophilic factor. Mann and colleagues [1] state that the acceptance of albumin is an individual decision by Jehovah's Witnesses. However, in conversation with Church Elders, we have learned that albumin is considered acceptable by the Church, based on the precedent that it passes freely between mother and fetus during pregnancy [2].References1. Mann MC, Votto J, Kambe J, McNamee MJ. Management of the severely anemic patient who refuses transfusion: lessons learned during the care of a Jehovah's Witness. Ann Intern Med. 1992; 117: 1042-8. Google Scholar2. The Watchtower. 1 Jun 1990:31. Google Scholar Author, Article, and Disclosure InformationAuthors: David Green, MDAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byUse of Erythropoietin in the Severely Anemic Jehovah's Witness Patient: Case Report and Review of the Literature 15 July 1993Volume 119, Issue 2Page: 169-170KeywordsAlbuminsErythropoietinFetusesPregnancy ePublished: 15 August 2000 Issue Published: 15 July 1993 Copyright & PermissionsCopyright © 1993 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
New Implant for Retinal Detachment Surgery
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
An Integrated Assessment Framework for Climate Change and Infectious Diseases
Authors: Nathan Y. Chan, Kristie L. Ebi, Fraser Smith, Thomas F. Wilson, Anne E. Smith
Journal: Environmental Health Perspectives (1999)

Many potential human health effects have been hypothesized to result either directly or indirectly from global climate change. Changes in the prevalence and spread of infectious diseases are some of the most widely cited potential effects of climate change, and could have significant consequences for human health as well as economic and societal impacts. These changes in disease incidence would be mediated through biologic, ecologic, sociologic, and epidemiologic processes that interact with each other and which may themselves be influenced by climate change. Although hypothesized infectious disease effects have been widely discussed, there have not yet been thorough quantitative studies addressing the many processes at work. In part this is because of the complexity of the many indirect and feedback interactions or mechanisms that bear on all aspects of the climate issue. It also results from the difficulty of including the multitude of always-changing determinants of these diseases. This paper proposes a framework for an integrated assessment of the impacts of climate change on infectious diseases. The framework allows identification of potentially important indirect interactions or mechanisms, identification of important research gaps, and a means of integrating targeted research from a variety of disciplines into an enhanced understanding of the whole system.
The use of imipramine in depressed patients with congestive heart failure
Authors: A. H. Glassman
Journal: JAMA (1983)

Previous studies of left ventricular performance (LVP) in depressed patients receiving tricyclic antidepressants have been performed on patients without severe heart disease. This study reports the effect of imipramine hydrochloride on LVP, assessed by radionuclide angiography, in a group of depressed patients with notable preexisting left ventricular dysfunction. Ejection fraction was measured at rest by first-pass radionuclide angiography before and after treatment with imipramine. Ejection fraction was unchanged during treatment, but seven of 15 patients experienced orthostatic hypotension of such severity that administration of the drug had to be discontinued. Plasma concentrations of the drug were essentially twice those usually seen. It is important to appreciate that although imipramine does not further impair resting LVP, this does not mean it is without risk. The physician must watch carefully for orthostatic hypotension when using imipramine in depressed patients with impaired LVP. (<i>JAMA</i>1983;250:1997-2001)
Diagnosis and management of Kawasaki disease
Authors: W. M. Gersony
Journal: JAMA (1991)

Kawasaki disease is an acute vasculitis characterized by mucosal inflammation, rash, cervical adenopathy, indurative edema of the hands and feet, and late membranous desquamation of the fingertips. Early cardiac effects include myocarditis (occasionally with congestive heart failure), pericardial inflammation, and, rarely, valve involvement. Coronary artery aneurysms are a long-term concern because coronary thrombosis with myocardial infarction can be a late manifestation. The origin of Kawasaki disease is unknown, but an infectious agent is most likely. Management consists of aspirin for control of fever and inflammatory manifestations and intravenous gamma globulin for the prevention of coronary aneurysm formation. Careful late follow-up is required, especially for patients with persistent coronary abnormalities. Giant aneurysms (&gt;8 mm) are more likely to progress to coronary obstructive disease, and coronary bypass grafts have been required for some patients. Late coronary artery manifestations in patients with mild early coronary dilatation have not been described. However, since long-term epidemiologic studies have not yet been performed, it is prudent to consider childhood Kawasaki disease to be a potential risk factor for coronary disease, especially in atherosclerosis-prone Western societies. (<i>JAMA</i>. 1991;265:2699-2703)
The Common Causes of Chronic Indigestion: Differential Diagnosis and Treatment.
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cavitating tumorous lesion of lung
Authors: James W. Wallace
Journal: JAMA (1969)

Dr. David A. Kumpe: This 41-year-old woman, a housewife, had a brief illness characterized by pleuritic pain on the right side, malaise, low-grade fever, and a dry, nonproductive cough. Physical and laboratory findings were normal, and chest roentgenograms were made (Figure). <h3>Discussion</h3> Dr. Jack R. Dreyfuss: Dr. Weber, would you like to comment? Dr. Alfred L. Weber: The main roentgenographic finding is a hazy, ill-defined, cavitated infiltrate in the apical posterior segment of the upper lobe of the right lung (Figure). There is no pleural reaction. The hilum is not enlarged, and I detect no enlarged lymph nodes. I do not see any other lesions. The heart is not remarkable, and the trachea is normal. At this point there are several possibilities, such as tuberculosis, fungus disease, Wegener's granulomatosis, bacterial pneumonia. It does not look like tumor, although this cannot be excluded entirely. Dr. Kumpe: The patient was treated with
Abstract 1420: Mitochondrial Arginase II Constrains Endothelial NOS Activity
Authors: Hyun Kyo LIM, Hyun Kyoung Lim, Sungwoo Ryoo, Alex Benjo, Karl Shuleri, Kevin Soucy, Daniel Nyhan, Artin Shoukas, Dan E Berkowitz
Journal: Circulation (2007)

Background: Arginase II is known as a major isoenzyme in the vascular endothelial cells of humans and other species and modulates endothelial nitric oxide synthase (eNOS) activity by regulating intracellular L-arginine bioavailability. We tested under hypothesis that subcellular localization of arginase II is confined to the mitochondria and mitochondrial arginase II deficiency reciprocally regulates the vascular endothelial NO production, contributes to improve endothelial dysfunction and decrease vascular stiffness. Methods and Results: Western blot, immunocytochem with Mitotracker and immunoEM confirmed that arginase II is confined predominantly but not exclusively to the mitochondria. Arginase activity was significantly reduced, whereas NO production was significantly increased in aorta and isolated endothelial cells from arginase II knock out (ArgII−/−) compared to WT mice. Vasorelaxation to acetylcholine (ACh) was markedly enhanced and vasoconstriction to phenylephrine (PE) was impaired in ArgII−/− rings. Furthermore inhibition of eNOS by N G -nitro-L-arginine methyl ester (L-NAME) impaired ACh response and restored PE response. The baseline pulse wave velocity was significantly decreased in ArgII −/− mice (3.30 ± 0.21 vs. 3.64 ± 0.12 m/s, ArgII −/− vs. WT, *p&lt;0.01), while 14 days of L-NAME treatment resulted in significant increase the PWV in both WT (4.23 ± 0.11 m/s, **p&lt;0.001) and ArgII −/− mice (4.36 ± 0.20 m/s, **p&lt;0.001). Conclusions: These data suggest that arginase II is predominantly confined to the mitochondria and this mitochondrial arginase II regulate the NO production, vascular endothelial function, and vascular stiffness by modulating eNOS activity.
Preclinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma
Authors: Esther Drent, Richard Groen, Willy Noort, Jeroen Lammerts van Bueren, Paul Parren, Jürgen Kuball, Zsolt Sebestyen, Niels van de Donk, Anton Martens, Henk Lokhorst, Tuna Mutis
Journal: Journal for ImmunoTherapy of Cancer (2015)

Meeting abstracts Adoptive transfer of T cells transduced with tumor-reactive Chimeric Antigen Receptors (CARs) is a promising strategy for cancer immunotherapy. The CD38 molecule, with its high and homogenous expression on Multiple Myeloma (MM) cells, appears a suitable target for antibody therapy
<i>Mycobacterium tuberculosis</i> infection induces il12rb1 splicing to generate a novel <i>IL-12Rβ1</i> isoform that enhances DC migration
Authors: Richard T. Robinson, Shabaana A. Khader, Cynthia A. Martino, Jeffrey J. Fountain, Maria Teixeira-Coelho, John E. Pearl, Stephen T. Smiley, Gary M. Winslow, David L. Woodland, Michael J. Walter, Jose R. Conejo-Garcia, Ueli Gubler, Andrea M. Cooper
Journal: The Journal of Experimental Medicine (2010)
Highlights from the Literature
Journal: Neuro-Oncology (2019)

Stereotactic radiosurgery for intracranial ependymomas: an international multicenter studyThe standard management of ependymomas consists of resection followed by external beam fractionated radiation therapy (RT). 1,2 Ependymomas that recur after failure of initial surgery and RT are difficult to manage, and both local and distant recurrences require further surgery or chemotherapy.Stereotactic radiosurgery (SRS) has been proposed as a minimally invasive salvage treatment. 3 The aim of the study of Kano et al 4 was to analyze the outcome of intracranial ependymoma patients who underwent SRS as a part of multimodality management.Seven centers participating in the International Gamma Knife Research Foundation identified 89 intracranial ependymoma patients who underwent SRS (113 tumors).The median patient age was 16.3 yrs (2.9-80).All patients had undergone previous surgical resection and radiation therapy (RT) of their ependymomas, and 40 had had previous chemotherapy.Grade 2 ependymomas were present in 42 patients (52 tumors) and grade 3 ependymomas in 48 patients (61 tumors).The median tumor volume was 2.2 cc (0.03-36.8) and the median margin dose was 15 Gy (9-24).Forty-seven (53%) patients were alive and 42 (47%) patients died at the last follow-up.The overall survival after SRS was 86% at 1 yr, 50% at 3 yrs, and 44% at 5 yrs.Smaller total tumor volume was associated with longer overall survival (P = 0.006).Twenty-two patients (grade 2: n = 9, grade 3: n = 13) developed additional recurrent ependymomas in the craniospinal axis.The progression-free survival after SRS was 71% at 1 yr, 56% at 3 yrs, and 48% at 5 yrs.Adult age, female sex, and smaller tumor were correlated significantly with longer progressionfree survival.Symptomatic adverse radiation effects were seen in 7 patients (8%), but were successfully managed with oral corticosteroids.The main limitation of this study is the retrospective nature and the lack of a control cohort of patients receiving repeated fractionated RT.Routine neuroimaging in the follow-up of patients with ependymomas may have likely led in recent years to an earlier detection of recurrence, thus favoring the use of radiosurgical instead conventional techniques.Overall, SRS provides another management option for residual or recurrent progressive intracranial ependymoma patients who have failed initial surgery and RT.Overall survival
Intracerebral hematoma in a hemophiliac. Combined surgical and factor VIII treatment
Authors: H. Friedman
Journal: JAMA (1971)

An intracerebral hematoma was successfully evacuated from a hemophiliac patient. A high-potency antihemolytic factor preparation was used. Comparing various methods of treatment we conclude that diagnostic studies and surgical treatment of intracranial hemorrhage can be safely carried out by this method.
AB0120 Primary sjogren’s syndrome associaed with anterior horn cell disorder
Authors: JC Tseng, HH Cheng, RJ Hu, LY Lu
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> Central nervous system (CNS) involvement in primary Sjogren’s syndrome (pSS) is controversial with regard to incidence, aetiology and pathogenesis. In the literature, the incidence of CNS-SS varies widely, ranging from rare to incidence rates of 20% to 25%. The clinical picture is diverse, ranging from mild cognitive symptoms to fatal cerebrovascular accidents. <h3>Objectives</h3> We describe a patient with pSS presenting with dysphagia and progressive respiratory failure resulting from anterior horn cell disorder. The disease responded to corticosteroids, hydroychloroquine and azathioprine treatment. To our knowledge this is the first case reported in the medical literature. <h3>Methods</h3> A 58-year-old woman had a one year history of dry eyes and dry mouth. She experienced progressive dysphagia and dyspnea ten days prior to admission. She developed progressive respiratory muscle weakness which resulted in respiratory failure and received mechanical ventilation during admission. Examination revealed symmetrically decreased muscle power without sensory impairment. Schirmer test was positive. Blood investigations revealed positive ANA, anti-SS-A and elevated IgG level up to 2820 mg/dl. Full blood cell count and creatine kinase level were normal. Sjogren’s syndrome was proved by minor salivary gland biopsy. Electromyography, nerve conduction velocity and evoked potentials studies showed anterior horn cell disorder. MRI of brain revealed negative finding. The disease improved with administration of corticosteroids, hydroxychloroquine and azathioprine. <h3>Results</h3> <h3>Conclusion</h3> Sjogren’s syndrome should be considered in the differential diagnosis of patients with motor neuron diseases. Prompt diagnosis and treatment prevent further morbidity and mortality. <h3>References</h3> Cox PD, Hales RE. CNS Sjogren’s syndrome: an underrecognized and underappreciated neuropsychiatric disorder. J Neuropsychiatry Clin Neurosci. 1999;11(2):241–7 Wright RA, O’Duffy JD, Rodriguez M. Improvement of myelopathy in Sjogren’s syndrome with chlorambucil and prednisolone therapy. Neurology 1999;52(2):386–8 Ioannidis JP, Moutsopoulos HM. Sjogren’s syndrome: too many associations, too limited evidence. The enigmatic example of CNS involvement. Semin Arthritis Rheum. 1999;29(1):1–3 Niemela RK, Hakala M. Primary Sjogren’s syndrome with severe central nervous system disease. Semin Arthritis Rheum. 1999;29(1):4-13
A phase I trial of bexarotene and docetaxel in patients with advanced solid tumors
Authors: S. M. Malik, J. L. Marshall, P. Ramzi, J. F. Deeken, M. J. Pishvaian, J. J. Hwang
Journal: Journal of Clinical Oncology (2008)

14512 Background: A phase I trial of bexarotene and docetaxel in patients with advanced solid tumors. Retinoids play critical roles in normal development and physiology by modulating cell growth, division, reproduction, differentiation, and immune function. Bexarotene (Bex) is a novel synthetic retinoid analogue binding preferentially to members of the RXR subclass of receptors. In a phase I trial of single agent Bex, patients with non-small cell lung cancer (NSCLC) had prolonged stabilization of disease and survival. Retinoids enhance docetaxel (D)induced apoptosis by causing down-regulation of Bcl-2, activation of RAR-gamma and altered expression Bcl-2/Bax. Methods: This Phase 1 study in patients (pts) with advanced neoplasms evaluated the safety and tolerability of fixed dose oral Bex at 400mg/m2 daily with escalating doses of D weekly for 3/4 weeks at 3 dose levels, 25, 30 & 35mg/m2, for up to 6 cycles. In pts exhibiting response or disease stabilization, treatment with Bex was continued until disease progression or intolerable toxicity. Cohorts consisted of 3 pts and were expanded to 6 pts if dose- limiting toxicity (DLT) was noted. Results: 19 pts were enrolled, including NSCLC (8), head & neck (2) esophageal (2) colorectal (2) cancers. 7 pts were treated at 25mg/m2, 6 at 30mg/m2 and 6 at 35mg/m2 of D. The MTD was D at 30mg/m2 with 400mg/m2of daily Bex. Hypothyroidism, hypertriglyceridemia, and fatigue were common.Two pts experienced grade 3 fatigue, and 1 each experienced grade 3 hypertriglyceridemia and hypothyroidism. Of 16 patients assessable for response, and 7 had stable disease for at least 2 cycles. One pt with NSCLC had a partial response that persisted for 8 cycles. 3 pts developed pulmonary toxicity (2 with radiation recall pneumonitis), 2 withdrew consent due to grade 3 fatigue. One pt died due to acute pulmonary hypertension secondary to pulmonary tumor emboli noted at autopsy. 5 pts are presently alive, two longest with NSCLC 35 & 22 months. Conclusions: MTD of D was 30mg/m2 in combination with daily dose Bex 400mg/m2. Care should be taken in patients who have been previously irradiated. A phase II trial of this combination at MTD as second line therapy in NSCLC is planned and correlative studies will be added. No significant financial relationships to disclose.
Relaxin decreases renal interstitial fibrosis and slows progression of renal disease1
Authors: Sandra L. Garber, Yelena Mirochnik, Carolyn S. Brecklin, Elaine N. Unemori, Ashok K. Singh, Leonid Slobodskoy, Beverly H. Grove, Jose A.L. Arruda, George Dunea
Journal: Kidney International (2001)
Some Aspects of the Cancer Problem: An Account of Researches Into the Nature and Control of Malignant Disease Commenced in the University of Liverpool in 1905, and Continued by the Liverpool Medical Research Organization (Formerly the Liverpool Cancer Committee), Together With Some of the Scientific Papers That Have Been Published.
Journal: JAMA (1931)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
New approaches for inflammatory bowel disease
Journal: JAMA (1990)

<h3>To the Editor.—</h3> We read with interest the article by Cotton<sup>1</sup>that summarizes recent reports of promising new medical therapies for inflammatory bowel disease. We are concerned, however, that the author's enthusiasm about the use of such drugs as mesalamine, hydroxychloroquine sulfate, methotrexate, and cyclosporine appears to have limited him from sounding a note of caution concerning some of the risks of prolonged use of certain drugs for the treatment of ulcerative colitis. We recently reported our clinical experience with the surgical management of 177 consecutive patients with severe ulcerative colitis using the ileoanal pouch procedure.<sup>2</sup>By the time these patients underwent colectomy, 14 (8%) had developed adenocarcinoma of the colon or rectum. In two patients, such extensive carcinoma was found at operation that the endorectal ileal pull-through procedure could not be performed. Pathological changes, ranging from low-grade dysplasia to frank carcinoma, were present in 52 (29%) of